Chapter 60: Drugs for Diabetes Mellitus

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, usually when we talk about a medical diagnosis, there's this expectation of clinical precision.

Right, like engineering.

Exactly, like engineering.

You break your arm, the x -ray shows that jagged white line and the doctor just points and says, there it is.

But then you look at the history of medicine and things get a little weird.

Oh, very weird.

Yeah.

Take diabetes mellitus.

Do you know where that name actually comes from?

It's a rather wild piece of medical history.

Diabetes comes from the Greek word for fountain.

And mellitus is the Latin word for honey.

Fountain and honey,

which sounds lovely, right?

Until you realize that ancient doctors literally diagnosed this disease by, well, observing patients producing massive fountain -like volumes of urine.

And then they would complete their diagnosis by smelling and, yes, actually tasting the patient's urine to see if it was sweet.

It is the absolute definition of diagnostic muddy waters.

And while we, thankfully, have much more sanitary diagnostic tools today, that underlying issue,

the body's inability to manage sugar, it remains one of the most complex puzzles in modern medicine.

It really does.

So today, we're taking you on a custom deep dive into chapter 60 of Linnea's Pharmacology for Nursing Care.

We're talking directly to you, the college nursing student.

Our mission today is to help you master the complex medications used to treat diabetes.

We're decoding the mechanisms so you can ace your exam and protect your future patients.

Absolutely.

We are going to stick strictly to the text, unpack the dense drug information, and really explore the cause and effect of these medications.

So let's just start at the very beginning.

We know diabetes has to do with sugar, but what is actually happening in the body to cause this metabolic chaos?

Well, the foundation here is that diabetes is primarily a disorder of carbohydrate metabolism.

But if we look at the bigger picture, it doesn't stop with carbohydrates.

Insulin deficiency ultimately disrupts the metabolism of proteins and lipids, too.

Without insulin, your body just cannot effectively utilize the fuel you consume.

So it's a total system failure.

Exactly.

The central pharmacology focus of this entire chapter, and really this whole subject, is how we manage that chaos through glycemic control, preventing catastrophic short -term and long -term complications.

I always like to visualize the pancreas as a factory.

And the textbook breaks this down beautifully in table 60 .1 when comparing type 1 and type 2 diabetes.

The factory analogy is great.

Yeah.

So if we use that in type 1 diabetes, the factory is essentially burned down, right?

That is a highly accurate way to look at it.

Type 1 diabetes, which accounts for only about 5 % of all cases, is an autoimmune disorder.

The patient's own immune system goes rogue and inappropriately destroys the pancreatic beta cells.

Those are the exact cells responsible for synthesizing insulin.

So the factory is gone.

Right.

Because of this destruction, insulin production eventually falls to absolute zero.

Wow.

But type 2, which is, what, like 90 % to 95 % of cases, that's totally different.

The factory is still standing.

Yes.

In type 2 diabetes, the factory is still working, at least initially.

The primary defect here is insulin resistance and impaired insulin secretion.

OK, so how does that work?

Well, the target tissues, meaning the liver, muscle, and adipose tissue,

they just stop responding effectively to the insulin that is circulating.

So the factory is making insulin delivery trucks.

But the stores, the cells, are just ignoring them.

Precisely.

And because the sugar isn't getting delivered, the factory works harder and harder until it exhausts itself trying to keep up.

That's exactly the progression.

And while type 2 is strongly linked to genetics and obesity, both types lead to severe short -term and long -term complications if left untreated.

Right, the textbook gets pretty intense here.

It has to.

Short -term, the textbook highlights hyperglycemia, hypoglycemia, and ketoacidosis.

Ketoacidosis, that's DKA, right?

Yes.

The physiology here shows that ketoacidosis is a common, potentially fatal risk for type 1 patients.

Because they have zero insulin, their bodies resort to breaking down massive amounts of fat for energy.

Which sounds like it would cause problems.

Huge problems.

That breakdown floods the blood with a split ketones.

But that crisis is relatively rare in type 2, because even a tiny amount of residual insulin can suppress that severe fat breakdown.

OK, so that's short -term.

But the long -term complications apply to both types.

And this is where the textbook gets incredibly sobering.

Cardiovascular disease, retinopathy causing blindness, nephropathy destroying the kidneys.

It's devastating.

I've always heard high blood sugar described as acting like tiny shards of glass circulating in the blood.

The shards of glass analogy perfectly captures the microvascular damage.

When blood glucose remains chronically elevated, it physically and chemically damages the innermost lining of the blood vessels.

Like scraping the insides.

Exactly.

In the tiny delicate capillaries of the eyes, this causes microanarysms and scarring, leading to blindness.

In the kidneys, it destroys the intricate filtering system, eventually requiring dialysis.

The book is also very specific about amputations.

It's not just diabetes causes bad feet.

It's this whole devastating chain reaction.

It is a perfect storm of pathology.

First, hyperglycemia provides a glucose -rich environment that bacteria absolutely love.

So infections thrive.

Simultaneously, diabetes suppresses immune function, so the body can't fight back.

Combine that with diabetic neuropathy, where nerve damage means the patient literally cannot feel the pain of a cut or a blister on their foot.

Oh, wow.

So they don't even know it's there.

Exactly.

A completely inconsequential infection goes unnoticed, becomes gangrenous, and necessitates amputation.

That is terrifying.

So if ancient doctors tasted urine, what is the modern equivalent?

How do we actually catch this metabolic chaos in the act before that microvascular damage happens?

We relied on three main diagnostic criteria today, as outlined in table 60 .2.

First, a fasting plasma glucose test.

If the patient hasn't eaten for at least eight hours and their glucose is 126 milligrams per deciliter or higher, that indicates diabetes.

OK, 126.

Second, an oral glucose tolerance test, measuring blood sugar two hours after drinking a heavy glucose load.

A result of 200 or higher is diagnostic.

Finally, the hemoglobin A1C test, which is crucial for long -term monitoring.

I see A1C ordered all the time in clinicals.

But how does a single blood draw tell us what the patient's blood sugar has been doing for months?

It comes down to the lifespan of a red blood cell, which is about 120 days.

As these cells float through the bloodstream, glucose naturally attaches itself to the hemoglobin molecule.

The higher the blood glucose has been over that 120 -day period, the higher the percentage of coated or glycated hemoglobin.

Well, that makes perfect sense.

Yeah, an A1C of 6 .5 % or higher is diagnostic for diabetes.

And for patients already diagnosed, the clinical goal per table 60 .3 is generally to keep that A1C below 7%.

So if keeping the A1C below 7 % is the target, what is our most direct weapon to force blood sugar down?

Like if a patient has type 1 and produces zero insulin, they absolutely must have exogenous insulin to survive.

Right.

To understand insulin as a drug, we have to look at its physiology.

Insulin is an anabolic hormone, meaning it is fundamentally constructive.

Constructive, meaning it builds things up.

Exactly.

It doesn't just passively open a door for glucose.

It actively forces cells to take up glucose, amino acids, and potassium.

It also promotes the conversion of that glucose into glycogen, securely storing it in the liver for later use.

The textbook lists a dizzying array of insulin preparations, though.

How do we keep them straight?

We categorize them by their duration of action.

You have your short duration, but rapid acting insulins like insulinless pro.

These are typically given right before meals.

Okay.

Then you have short duration, but slower acting, which is your regular human insulin.

Next is intermediate duration, which is NPH insulin.

Wait, let me jump in with a quick question on NPH.

The book has a very specific administration alert about how it looks compared to the others.

Yes, a vital nursing implication.

NPH is a cloudy suspension.

Cloudy.

Yes.

All other insulins are clear solutions.

Because it is a suspension, the particles settle at the bottom of the vial.

You must gently agitate it, rolling it between your hands, not shaking it to mix it before drawing it up.

Roll.

Don't shake.

Got it.

Finally, you have your long and ultra long duration insulins like glurgine and deglutec, which provide a steady basal level of insulin over 24 hours without a pronounced peak.

Okay, here is where I get a bit confused by the textbook's clinical advice.

It emphasizes that we want tight glycemic control to prevent all those horrible long -term complications like kidney failure and blindness.

Right.

But then it spends pages warning about the major risks of hypoglycemia.

If normal blood sugar is the ultimate goal, why is tight control sometimes considered dangerous?

This is one of the most difficult clinical judgments a healthcare team faces.

The tighter the control, the closer you are keeping the patient's blood sugar to the lower end of the normal range.

So there's less wiggle room.

Exactly.

This shrinks the margin for error to almost nothing.

Even a modest overdose of insulin, an unexpectedly intense workout, or simply skipping a snack, can drop them off a cliff into severe, life -threatening hypoglycemia, meaning blood glucose drops dangerously low, typically under 70 milligrams per deciliter.

And as a nurse, you are the front line for catching that drop.

The symptoms come on fast, right?

Pekacardia, palpitations, sweating, confusion, and overwhelming fatigue.

They do.

And you must monitor for drug interactions that complicate this.

Alcohol can dangerously intensify insulin -induced hypoglycemia.

Well, that's good to know.

On the flip side, hyperglycemic agents like glucocorticoids counteract insulin.

A patient placed on high -dose steroids for an inflammatory condition will likely see their blood sugar spike, meaning their normal insulin dose won't be enough.

So insulin is non -negotiable for type 1.

What about the 90 to 95 % of patients with type 2 diabetes?

The factory is still producing somewhat.

The textbook notes we usually start them on an oral drug.

Yes, immediately.

And the undisputed king of oral antibiotics is metformin.

Metformin belongs to a class called biguanides.

And it is fascinating because of what it does not do.

It does not stimulate the pancreas to make more insulin.

I always picture metformin as a giant bouncer standing at the door of the liver.

The liver naturally stores and releases sugar, but metformin just stands there with its arms crossed, telling the liver, hey, we have enough glucose out there in the blood, stop letting more out.

That analogy perfectly captures its primary mechanism of action.

It inhibits glucose production in the liver.

Nice.

Additionally, it sensitizes the insulin receptors in muscle and fat, helping the cells finally listen to the insulin that is already present, and it slightly reduces glucose absorption in the gut.

Because it's a bouncer, not an insulin stimulator, the book highlights a massive safety benefit.

It carries almost zero risk of hypoglycemia when used by itself.

The patient won't suddenly crash just because they skipped lunch.

But we must discuss its adverse effects.

Gastrointestinal upset is incredibly common, decreased appetite, nausea, and diarrhea.

However, the textbook highlights a very specific black box warning lactic acidosis.

It is rare, but it carries a 50 % mortality rate.

Wait, why does a blood sugar drug cause a lethal buildup of acid?

It ties directly into metformin's pharmacokinetics.

Metformin is not metabolized by the liver.

It is excreted entirely unchanged by the kidneys.

Okay, so it relies heavily on the kidneys.

Exactly.

If a patient has renal impairment, the kidneys cannot clear the drug.

Metformin rapidly accumulates to toxic levels.

This toxicity inhibits the mitochondrial oxidation of lactic acid, causing it to build up fatally in the bloodstream.

Wait, if kidney function is the linchpin for keeping metformin safe,

what happens if a patient goes to the hospital for like a routine CT scan?

Radiology uses contrast dye, and the textbook has a glaring nursing safety alert about that.

You're exactly right.

Iodinated contrast dye can cause acute temporary renal failure.

Oh wow.

If a patient takes their metformin while their kidneys are stunned by the dye, the drug will accumulate, leading straight to lactic acidosis.

That is terrifying.

Therefore, metformin must be stopped before elective radiography and held for 48 hours afterward, only resuming once you verify their kidney function has returned to normal.

Patients also need to know that alcohol heavily intensifies the risk of lactic acidosis.

So metformin tells the liver to stop producing sugar, but what happens when the liver's bouncer isn't enough?

Like if the cells are still starving for sugar, we have no choice but to force the pancreas to work harder.

Right.

That leads us to the insulin secretagogues and the sulfonylerias and the meglutinides, which are also called glenides.

Secretagogues, so try saying that three times fast.

It's a mouthful.

Sulfonylerias include drugs like gliposide, gliburide, and glenioride.

Glenides include ricaglinide and nahaglinide.

Their mechanism of action is forceful and direct.

They actively drive blood glucose down by physically stimulating the pancreatic beta cells to release more insulin.

Calls an effect.

Because they are actively forcing insulin out, the major side effect has to be hypoglycemia.

Also going back to what we learned about insulin being an anabolic storage hormone,

if these drugs increase insulin, they inherently cause weight gain.

The physiology guarantees those side effects.

And for nursing administration, especially with the glenides, timing is everything.

Glenides are fast and short -acting.

The nurse must ensure the patient eats no later than 30 minutes after taking the dose.

Wait, if sulfonylerias just blindly whip the pancreas to release insulin, what if the patient is in the hospital and has an Eden?

Doesn't the drug just keep working and crash their blood sugar?

It absolutely does.

That is a critical nursing responsibility.

You must hold the drug if the patient is NPO, meaning receiving nothing by mouth.

Giving a sulfonyleria to a fasting patient is a guaranteed path to severe hypoglycemia.

You also have to educate patients about a severe drug interaction.

Combining sulfonylerias with alcohol can cause a disulfiram -like reaction.

A disulfiram reaction that's the intense, violently ill -femed, severe flushing palpitations and nausea.

Yes.

Definitely not a fun Friday night.

To have squeezing the pancreas causes too much weight gain and hypoglycemia, how else can we manipulate the body?

Can we just make the cells highly sensitive to the insulin we already have or block sugar from entering the body in the first place?

Let's look at the sensitizers first.

The phyazoladenatogenes, or glitazones, like pyglitazone.

Their mechanism is incredibly specific.

They activate a receptor in the cell nucleus called PPAR gamma.

PPAR gamma.

Turning this receptor on drastically reduces cellular insulin resistance.

The adverse effects listed here are severe, though.

Fluid retention is a massive one.

The activation of that PPAR gamma receptor inadvertently causes the kidneys to retain sodium and water.

This fluid retention expands blood volume, which can lead to severe heart failure.

So nurses have to be on high alert for that.

Absolutely.

Nurses have to assess these patients constantly for dyspnea, edema, and rapid weight gain.

Glitazones can also cause liver injury, and oddly enough, they promote ovulation in inovulatory premenopausal patients, which can cause unintended pregnancies.

Plus, there is a noted risk of bladder cancer.

Goodness.

Then we have the carb blockers, the alpha -glucophidase inhibitors like Alcarbose.

The mechanism makes total sense.

They act locally in the intestine to inhibit the enzyme that breaks down complex carbs, delaying their absorption into the bloodstream.

The cause and effect of the side effects is very predictable here.

Because you have all these leftover undigested carbohydrates sitting in the gut, intestinal bacteria have a field day fermenting them.

Which means?

The result is significant flatulence, abdominal cramps, and diarrhea.

Okay, reading this section actually gave me a huge aha moment about a classic nursing exam trap.

Oh really, let's hear it.

If a patient is taking a Carbose and they become hypoglycemic,

standard table sugar won't work to save them because table sugar is sucrose, a complex carb, and the drug specifically blocks the breakdown of complex carbs.

Exactly.

If you try to give them a regular sugary juice or candy,

the drug stops it from being absorbed.

You must use pure glucose tabs.

That shows exactly why understanding the mechanism of action is non -negotiable.

So we've manipulated the liver, the pancreas, the cells, and the gut.

What other pathways can we exploit?

What's left?

We can modulate specific gut hormones and we can utilize the kidneys.

Okay, let's talk about the hormones first.

The DPP4 inhibitors, or glyptins, like cytoglyptin.

To understand these, we have to look at the incretin system.

After you eat a meal, your intestines release incretin hormones.

These hormones naturally tell the pancreas, hey, food is here, release insulin and suppress glucagon.

The body also produces an enzyme called DPT4 that quickly destroys those incretins to keep them from overacting.

The glyptins simply block the destroyer.

They protect the incretins.

Exactly.

They inhibit the DPP4 enzyme, allowing the body's natural incretin hormones to stay active longer, enhancing insulin release.

The adverse effects are generally mild, though there is a rare but serious risk of pancreatitis and hypersensitivity reactions.

Then we have the SGLT2 inhibitors, like impagliflozin.

Honestly, this is my favorite mechanism in the whole chapter.

It is very unique.

Yeah, usually the SGLT2 transporters in your kidneys act like sponges, reabsorbing glucose back into the blood so you don't pee it out.

These drugs intentionally block that transporter.

It completely changes the metabolic approach.

By blocking reabsorption, it causes the patient to excrete massive amounts of glucose directly into their urine.

It's like opening the floodgates.

Instead of trying to store the sugar or stop it from being made, this drug just says, forget it, let's just flush it out of the body entirely.

And again, osmotic diuresis dictates the side effects because you are peeing out sugar -rich urine, bacteria and fungi thrive in the genitourinary tract.

As a nurse, you are monitoring for genital mycotic or yeast infections and serious UTIs.

Furthermore,

because glucose pulls water with it as it exits the body, patients lose fluid volume.

This can lead to postural hypotension, dizziness and dehydration, especially in older adults.

Okay, so we've covered pills, but there's a whole class of non -insulin medications that patients inject subcutaneously operating on totally different pathways.

The primary group here is the GLP -1 receptor agonists or incretin mimetics,

like exenotide and allera glutide.

Remember how gliptons stopped the destruction of natural incretins?

Well, GLP -1 agonists take a more direct route.

They mimic the incretin hormones themselves.

They drastically slow gastric emptying, stimulate glucose -dependent insulin release and signal the brain to suppress appetite.

And because they suppress appetite and keep the stomach full longer, they induce significant weight loss.

But the textbook emphasizes a black box warning here regarding the thyroid.

Yes, in rodent studies, these drugs cause thyroid C -cell tumors, specifically medullary thyroid carcinoma.

While it's uncertain if this translates identically to humans, they are contraindicated in anyone with a personal or family history of these specific tumors.

That's a major alert.

The chapter also mentions the newest innovation, terzepotide or monjaro.

It's the first drug to be a dual agonist.

It mimics both GLP -1 and GIP receptors compounding that physiological feeling of satiety even more.

Finally, we have the amylin mimetics, like pramlentide.

Amylin is a hormone naturally co -released with insulin to delay gastric emptying.

But there's a huge safety warning here.

Because it's prescribed alongside mealtime insulin, there is a massive risk for severe hypoglycemia.

Huge risk.

Now, if these GLP -1s and amylin mimetics are injected just like insulin, do patients use the same injection spots?

They do use the same general areas, subcutaneous tissue in the abdomen, thigh or upper arm, always rotating sites.

But a crucial patient education point is teaching them to carefully keep these non -insulin injections separate from their insulin injection sites to avoid altering absorption rates.

That makes sense.

Furthermore, there is a critical nursing implication for all of these injectables regarding oral medications.

Right, because they physically slow down the digestive tract, they will delay the absorption of any oral drug the patient takes.

Yes.

That is dangerous if they rely on peak levels of an antibiotic, a painkiller or an oral contraceptive.

You have to teach the patient to take their oral medications at least one hour before taking their injectable diabetes medication.

If we synthesize the core philosophy of chapter 60, managing diabetes pharmacology is an incredibly delicate balancing act.

You are constantly trying to drive glucose down to prevent the devastating microvascular damage, the blindness, the kidney failure, the amputations, while safely avoiding the immediate life -threatening cliff of hypoglycemia.

That's walking a physiological tightrope every single day.

It really is, and building on that, I want to leave you, the nursing student, with a final thought to mull over.

We've talked extensively about the mechanics of these drakes today.

How sulfonylureas physically force insulin out, how glutazones open the nuclear receptors, or how SGLT2 inhibitors create a glucose floodgate in the kidneys.

Right, the science.

But think about the daily lived reality of your patient.

They have to orchestrate their meals,

rigorously monitor their physical activity, and perfectly time multiple complex medications every single day for the rest of their lives.

Yeah, that is a lot.

The true challenge isn't just knowing the pharmacology.

It's asking yourself,

how will you, as their nurse, empower them to manage this lifelong metabolic puzzle without feeling defeated by it?

That is exactly what nursing is all about.

Taking the dense science and making it human.

To the nursing student listening to this, thank you for trusting us with your prep.

The Deep Dive team is rooting for you.

Good luck on your pharmacology exam, and more importantly, good luck in your future clinical practice.

Remember, you aren't just treating a fountain of honey, you're treating a whole person.

Catch you next time.